{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:20Z","timestamp":1793196800319,"version":"4.5.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>Varying hair textures and hair care practices contribute to nuances in clinical presentation and management of scalp psoriasis across diverse patient populations. Cohort B of the VISIBLE trial enrolled participants with moderate to severe scalp psoriasis and skin of color, across the skin-tone spectrum.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among participants with moderate to severe scalp psoriasis and skin of color over 48 weeks.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This ongoing phase 3b, randomized clinical trial at 45 sites in the US and Canada enrolled adults with skin of color and moderate to severe scalp psoriasis (scalp surface area [SSA] \u226530%; Psoriasis Scalp Severity Index [PSSI] \u226512; scalp-specific Investigator\u2019s Global Assessment [ss-IGA] score \u22653; \u22651 nonscalp plaque). Data were collected from September 2022 to June 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0, 4, and every 8 weeks, or placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, and every 8 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Coprimary end points were ss-IGA score of 0 or 1 (ss-IGA 0\/1) and 90% or greater improvement in PSSI (PSSI 90) at week 16 (guselkumab vs placebo). Major secondary end points included ss-IGA 0 (complete scalp clearance), PSSI 100, percentage changes from baseline in PSSI and SSA, changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms score, and 4-point or greater reduction in Scalp Itch Numeric Rating Scale (NRS) score.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 108 participants (81 randomized to guselkumab; 27 randomized to placebo), 100 (92.6%) completed 48 weeks of treatment. The mean (SD) age overall was 42.5 (13.6) years, and 58 participants (56.9%) were male. At the week 16 primary end point, in the guselkumab (n\u2009=\u200976) vs placebo (n\u2009=\u200926) groups, respectively, response rates were as follows: ss-IGA 0\/1, 68.4% (n\u2009=\u200952) vs 11.5% (n\u2009=\u20093) (P<\/jats:italic>\u2009&amp;lt;\u2009.001); PSSI 90, 65.8% (n\u2009=\u200950) vs 3.8% (n\u2009=\u20091) (P<\/jats:italic>\u2009&amp;lt;\u2009.001); ss-IGA 0, 57.9% (n\u2009=\u200944) vs 3.8% (n\u2009=\u20091) (P<\/jats:italic>\u2009&amp;lt;\u2009.001); PSSI 100, 59.2% (n\u2009=\u200945) vs 3.8% (n\u2009=\u20091) (P<\/jats:italic>\u2009&amp;lt;\u2009.001); 4-point or greater reduction in Scalp Itch NRS score (in those with a baseline score of at least 4), 69.4% (n\u2009=\u200950 of 72) vs 24.0% (n\u2009=\u20096 of 25) (P<\/jats:italic>\u2009&amp;lt;\u2009.001). Guselkumab efficacy increased and was maintained through week 48, when guselkumab-randomized participants achieved mean (SD) percentage improvements in PSSI and SSA of 94.6% (12.2%) and 94.8% (16.2%), respectively, and 51 (67.1%) achieved ss-IGA 0. DLQI and PSSD symptoms score least-squares mean changes were \u20139.7 (95% CI, \u221211.1 to \u22128.2) vs \u20132.2 (95% CI, \u22124.8 to 0.4) (P<\/jats:italic>\u2009&amp;lt;\u2009.001) and \u201344.8 (95% CI, \u221250.6 to \u221239.1) vs \u20138.3 (95% CI, \u221218.4 to 1.9) (P<\/jats:italic>\u2009&amp;lt;\u2009.001), respectively, with sustained improvements through week 48. Through week 16, infections were the most common adverse events in the guselkumab (n\u2009=\u200912; 14.8%) and placebo (n\u2009=\u20091; 3.7%) groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, after 3 doses of guselkumab, most participants achieved significant scalp clearance and clinically meaningful quality-of-life improvements; improvements increased and were maintained through week 48.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05272150<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1849","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:31:23Z","timestamp":1750851083000},"page":"912","source":"Crossref","is-referenced-by-count":9,"title":["Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones"],"prefix":"10.1001","volume":"161","author":[{"given":"Amy","family":"McMichael","sequence":"first","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut"},{"name":"Central Connecticut Dermatology, Cromwell"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System, West Bloomfield, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Alkousakis","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Choi","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Synergy Dermatology, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian O.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Nashville Skin Comprehensive Dermatology Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[{"name":"Center for Clinical Studies, Webster, Texas"},{"name":"University of Texas Health Science Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Chan","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Rowland","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Enverus Medical Research, Surrey, British Columbia, Canada"},{"name":"University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[{"name":"The Lynde Institute for Dermatology & Lynderm Research Inc, Markham, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"FACET Dermatology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Park-Wyllie","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ma","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jeyarajah","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Long","family":"Gao","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Smith","sequence":"additional","affiliation":[{"name":"California Dermatology & Clinical Research Institute, Encinitas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Moore","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Dallas, Texas"},{"name":"Arlington Research Center, Arlington, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Vashi","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chesahna","family":"Kindred","sequence":"additional","affiliation":[{"name":"Kindred Hair & Skin Center, Marriottsville, Maryland"},{"name":"Howard University College of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"The Grimes Center for Medical and Aesthetic Dermatology, Vitiligo and Pigmentation Institute of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"Innovative Dermatology, Plano, Texas"},{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Taylor","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Alexis","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VISIBLE Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaggi","family":"Rao","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adam","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Prajapati","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouzeh","family":"Niakosari","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Hanna","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Raman","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carrasco","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Clay-Cather","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Couvillion","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dhawan","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fretzin","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garcia-Zuazaga","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Getz","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lee","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Amster","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Dehesa","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stoll","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Boote","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlada","family":"Groysman","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Schlessinger","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Burgess","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Tung","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffani","family":"Hamilton","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Joyce","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Travers","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Browning","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Krell","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tory","family":"Sullivan","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Radusky","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Callender","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Weiss","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wallace","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Kerdel","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Reed","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pelle","sequence":"additional","affiliation":[{"name":"for the VISIBLE Trial Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi250027r1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000017972","article-title":"Evaluation of topical drug treatment in psoriasis.","volume":"197","author":"van de Kerkhof","year":"1998","journal-title":"Dermatology"},{"key":"doi250027r2","first-page":"68","article-title":"Malaysian Psoriasis Registry\u2014preliminary report of a pilot study using a newly revised registry form.","volume":"63 Suppl C","author":"Chang","year":"2008","journal-title":"Med J Malaysia"},{"issue":"3","key":"doi250027r3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","article-title":"Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management.","volume":"11","author":"Mosca","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"doi250027r4","first-page":"912","article-title":"Scalp psoriasis: an overview of the disease and available therapies.","volume":"9","author":"Crowley","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"doi250027r5","first-page":"1089","article-title":"Dermatologic conditions in skin of color compared to white patients: similarities, differences, and special considerations.","volume":"315","author":"Chatrath","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"doi250027r6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/ced.12715","article-title":"Psoriatic alopecia.","volume":"40","author":"George","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi250027r7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00128071-200102030-00005","article-title":"Psoriasis of the scalp: diagnosis and management.","volume":"2","author":"van de Kerkhof","year":"2001","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"doi250027r8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/09546634.2012.742176","article-title":"Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group.","volume":"25","author":"Frez","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"2S","key":"doi250027r9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12788\/cutis.0038","article-title":"Psoriasis in patients of color: differences in morphology, clinical presentation, and treatment.","volume":"106","author":"Nicholas","year":"2020","journal-title":"Cutis"},{"issue":"11","key":"doi250027r10","first-page":"16","article-title":"Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.","volume":"7","author":"Alexis","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"doi250027r11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups.","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"doi250027r12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.36849\/JDD.7090","article-title":"Evolving concepts in psoriasis: special considerations for patients with skin of color, skin barrier dysfunction, and the role of adjunctive skin care.","volume":"21","author":"Alexis","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"doi250027r13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","article-title":"Unmet need in people with psoriasis and skin of color in Canada and the United States.","volume":"12","author":"Yadav","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi250027r14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamadermatol.2024.5103","article-title":"Improving diversity in a novel psoriasis study: VISIBLE as a framework for clinical trial quality improvement.","volume":"161","author":"Alexis","year":"2025","journal-title":"JAMA Dermatol"},{"key":"doi250027r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1836","article-title":"Guselkumab for moderate to severe psoriasis across all skin tones: the VISIBLE Cohort A randomized clinical trial.","author":"Alexis","year":"2025","journal-title":"JAMA Dermatol"},{"key":"doi250027r16","first-page":"33","article-title":"Soleil et peau.","volume":"2","author":"Fitzpatrick","year":"1975","journal-title":"J Med Esthet"},{"issue":"6","key":"doi250027r17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","article-title":"The validity and practicality of sun-reactive skin types I through VI.","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi250027r18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials.","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi250027r19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000051731","article-title":"Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients.","volume":"203","author":"Tha\u00e7i","year":"2001","journal-title":"Dermatology"},{"issue":"1","key":"doi250027r20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","article-title":"Scalp psoriasis.","volume":"9","author":"Wozel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"doi250027r21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jaad.2019.01.022","article-title":"Rule of thumb: a simple tool to estimate 1% scalp surface area.","volume":"81","author":"Wambier","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250027r22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi250027r23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi250027r24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/09546634.2019.1577546","article-title":"Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.","volume":"30","author":"Wang","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi250027r25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdds.2015.07.004","article-title":"Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary.","volume":"20","author":"Feldman","year":"2016","journal-title":"J Dermatol Dermatol Surg"},{"issue":"4","key":"doi250027r26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/09546634.2015.1114567","article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary.","volume":"27","author":"Mathias","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"doi250027r27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250027r28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250027r29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi250027r30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09546634.2017.1364694","article-title":"Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.","volume":"30","author":"Armstrong","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"doi250027r31","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.18672","article-title":"Guselkumab in patients with scalp psoriasis: a post hoc analysis of the VOYAGE 2 phase III randomized clinical trial.","volume":"104","author":"Sonkoly","year":"2024","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi250027r32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi250027r33","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi250027r34","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jdv.15450","article-title":"Itch: an under-recognized problem in psoriasis.","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi250027r35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ejp.768","article-title":"Pruritus in psoriasis: an update.","volume":"20","author":"Szepietowski","year":"2016","journal-title":"Eur J Pain"},{"issue":"5","key":"doi250027r36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi250027r37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/09546634.2019.1572865","article-title":"Psoriasis-associated itch: etiology, assessment, impact, and management.","volume":"31","author":"Pithadia","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi250027r38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5?years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi250027r39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis.","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"doi250027r40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250027r41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi250027r42","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jaad.2020.02.025","article-title":"Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: a survey study.","volume":"83","author":"Amico","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250027r43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2310\/7750.2009.08077","article-title":"Postinflammatory hyperpigmentation.","volume":"13","author":"Taylor","year":"2009","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"doi250027r44","first-page":"377","article-title":"Improved quality of life with effective treatment of facial melasma: the pigment trial.","volume":"3","author":"Balkrishnan","year":"2004","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi250027r45","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaad.2021.02.010","article-title":"Measurement and prediction of the severity of postinflammatory dyspigmentation after resolution of psoriatic plaques in patients treated with biologic therapy.","volume":"86","author":"Chiu","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835458\/jamadermatology_mcmichael_2025_oi_250027_1757438053.51714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:49Z","timestamp":1758121249000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835458"}},"subtitle":["Cohort B of the VISIBLE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1849","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}